Suppr超能文献

解析癌症免疫治疗中的调节性T细胞动态:机制、意义及治疗创新

Deciphering Regulatory T-Cell Dynamics in Cancer Immunotherapy: Mechanisms, Implications, and Therapeutic Innovations.

作者信息

Bhattacharya Sankha, Paraskar Gaurav, Jha Megha, Gupta Girdhari Lal, Prajapati Bhupendra G

机构信息

School of Pharmacy and Technology Management, SVKM'S NMIMS Deemed-to-be University, Shirpur, Maharashtra 425405, India.

Shree. S. K. Patel College of Pharmaceutical Education and Research, Ganpat University, Kherva, Gujarat 384012, India.

出版信息

ACS Pharmacol Transl Sci. 2024 Jul 3;7(8):2215-2236. doi: 10.1021/acsptsci.4c00156. eCollection 2024 Aug 9.

Abstract

This Review explores how tumor-associated regulatory cells (Tregs) affect cancer immunotherapy. It shows how Tregs play a role in keeping the immune system in check, how cancers grow, and how well immunotherapy work. Tregs use many ways to suppress the immune system, and these ways are affected by the tumor microenvironment (TME). New approaches to cancer therapy are showing promise, such as targeting Treg checkpoint receptors precisely and using Fc-engineered antibodies. It is important to tailor treatments to each patient's TME in order to provide personalized care. Understanding Treg biology is essential for creating effective cancer treatments and improving the long-term outcomes of immunotherapy.

摘要

本综述探讨了肿瘤相关调节性T细胞(Tregs)如何影响癌症免疫治疗。它展示了Tregs如何在控制免疫系统、癌症生长以及免疫治疗效果方面发挥作用。Tregs通过多种方式抑制免疫系统,而这些方式会受到肿瘤微环境(TME)的影响。癌症治疗的新方法显示出了前景,例如精确靶向Treg检查点受体以及使用Fc工程抗体。根据每位患者的TME量身定制治疗方案以提供个性化护理非常重要。了解Treg生物学对于开发有效的癌症治疗方法和改善免疫治疗的长期效果至关重要。

相似文献

1
Deciphering Regulatory T-Cell Dynamics in Cancer Immunotherapy: Mechanisms, Implications, and Therapeutic Innovations.
ACS Pharmacol Transl Sci. 2024 Jul 3;7(8):2215-2236. doi: 10.1021/acsptsci.4c00156. eCollection 2024 Aug 9.
2
Tumor microenvironment and immunotherapy: from bench to bedside.
Med Oncol. 2025 Jun 8;42(7):244. doi: 10.1007/s12032-025-02818-x.
3
The health economics of insulin therapy: How do we address the rising demands, costs, inequalities and barriers to achieving optimal outcomes.
Diabetes Obes Metab. 2025 Jul;27 Suppl 5(Suppl 5):24-35. doi: 10.1111/dom.16488. Epub 2025 Jun 4.
4
New horizons in B-cell lymphoma immunotherapy: From immune checkpoints to precision medicine.
Neoplasia. 2025 Jun 30;67:101206. doi: 10.1016/j.neo.2025.101206.
6
Management of urinary stones by experts in stone disease (ESD 2025).
Arch Ital Urol Androl. 2025 Jun 30;97(2):14085. doi: 10.4081/aiua.2025.14085.
7
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.
Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340.
8
Dietary impacts on prostate cancer immunotherapy.
Immunotherapy. 2025 May;17(7):525-536. doi: 10.1080/1750743X.2025.2511472. Epub 2025 May 29.
9
Systemic treatments for metastatic cutaneous melanoma.
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.

引用本文的文献

1
MALT1 Inhibitors for Treating Cancer and Immunological Diseases.
ACS Med Chem Lett. 2024 Aug 20;15(9):1419-1420. doi: 10.1021/acsmedchemlett.4c00390. eCollection 2024 Sep 12.

本文引用的文献

1
Adipose-tissue Treg cells restrain differentiation of stromal adipocyte precursors to promote insulin sensitivity and metabolic homeostasis.
Immunity. 2024 Jun 11;57(6):1345-1359.e5. doi: 10.1016/j.immuni.2024.04.002. Epub 2024 Apr 30.
2
Establishment of novel anti-TIM-3 antibodies interfering with its binding to ligands.
Heliyon. 2024 Mar 18;10(7):e28126. doi: 10.1016/j.heliyon.2024.e28126. eCollection 2024 Apr 15.
4
Development of LAG-3/FGL1 blocking peptide and combination with radiotherapy for cancer immunotherapy.
Acta Pharm Sin B. 2024 Mar;14(3):1150-1165. doi: 10.1016/j.apsb.2023.12.011. Epub 2023 Dec 19.
7
The paradoxical role of cytokines and chemokines at the tumor microenvironment: a comprehensive review.
Eur J Med Res. 2024 Feb 15;29(1):124. doi: 10.1186/s40001-024-01711-z.
8
Regulation of T cells in the tumor microenvironment by histone methylation: LSD1 inhibition-a new direction for enhancing immunotherapy.
Heliyon. 2024 Jan 13;10(2):e24457. doi: 10.1016/j.heliyon.2024.e24457. eCollection 2024 Jan 30.
9
Advance in the role of chemokines/chemokine receptors in carcinogenesis: Focus on pancreatic cancer.
Eur J Pharmacol. 2024 Mar 15;967:176357. doi: 10.1016/j.ejphar.2024.176357. Epub 2024 Feb 1.
10
TIM-3 inhibitors: a promising strategy for tumor immunotherapy.
Trends Mol Med. 2024 Mar;30(3):202-203. doi: 10.1016/j.molmed.2024.01.004. Epub 2024 Jan 31.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验